FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
First tracked pre-IPO filing for this issuer.
Price $7.00 · Range $6.00 to $8.00 · 2,500,000 shares · Gross proceeds $17,500,000
common stock · Exchange NASDAQ · Ticker RGNA · Use of proceeds 60% sales and marketing, 27% R&D and clinical studies, 10% working capital, 3% machine equipment and facility upgrades · Underwriters StoneX Financial Inc.
Regenlab USA Inc. reports diversified revenue across products (RegenKit, CellularMatrix, Wound Care) and geographies (Europe, US, Asia). The MSK segment remains dominant, with significant growth in wound care driven by the MiMedx partnership. Core PRP+HA technology demonstrates clinical efficacy in knee osteoarthritis, with ongoing FDA PMA submissions. 1H 2026 operating income reached $2.1M, reflecting improved performance post-factory relocations and U.S. channel realignment. The company targets U.S. market expansion, EU/Asia growth via distribution partners, and regulatory milestones for CellularMatrix by mid-2027.
2026-10-28 · 0001829126-26-011590
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Range $6.00 to $8.00 · 2,500,000 shares · Gross proceeds $17,500,000
Common Stock · Exchange Nasdaq · Ticker RGNA · Over-allotment 375,000 · 3% warrants exercisable at 125% of public offering price for 4.5 years starting 180 days after offering · Use of proceeds For sales and marketing, machine equipment, R&D, and regulatory expenses · Flags warrants · Underwriters StoneX Financial Inc.
Regenlab USA Inc. reports revenue growth, with total revenue increasing to $29.32 million in 2026 from $24.22 million in 2025. The U.S. market saw significant expansion, driven by a distribution agreement with MiMedx for wound care products, contributing $4.12 million in revenue. Gross profit rose to $18.27 million for the six months ended June 2026, and operating income improved to $2.10 million compared to an operating loss of $0.77 million in the same period in 2025. The company's focus on PRP and Cellular Matrix products remains central, with these lines accounting for 90% of total revenues. However, net losses persist, with a net loss of $0.07 million in the first half of 2026.
2026-10-27 · 0001829126-26-011539
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
common · Exchange Nasdaq · Ticker RGNA · Representative's warrants to purchase 3% of shares issued in offering · Use of proceeds Sales and marketing, machine equipment, R&D, and working capital
Regenlab USA Inc. reported $49.17 million in product sales for 2025, a 1.6% increase from 2024, driven by growth in Europe and international markets despite a U.S. sales decline due to channel realignment. The company's revenue is concentrated in PRP kits (62% of 2025 revenue) and Cellular Matrix products (28.6%), which together accounted for 90% of total revenue. Operating income dropped 80.59% year-over-year to $0.68 million due to a $2.25 million increase in R&D expenses. The company expanded its footprint with a new factory in France and the U.S., and a 2025 distribution agreement with MiMedx for U.S. wound care products. Interim results for H1 2026 showed 21% revenue growth, with U.S. wound care sales surging due to the MiMedx partnership.
2026-09-25 · 0001829126-26-010431
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Regenlab USA Inc. reported significant revenue growth in 2026, driven by a 42% increase in total revenue to $16.357 million for the three months ended March 2026 compared to $11.492 million in the same period in 2025. The U.S. market saw a major shift, with revenue contribution rising from 20% to 50% due to an exclusive distribution agreement with MiMedx for wound care products, which generated $3.75 million in revenue. Gross profit improved by $5.2 million, and operating income turned positive at $4.626 million in Q1 2026 compared to a net loss of $0.651 million in Q1 2025. The company also highlighted expanded R&D efforts for market access in the U.S. and Europe, with key projects including the RegenMatrix clinical study and Cellular Matrix RL-04 initiative.
2026-06-16 · 0001829126-26-006533
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Regenlab USA Inc. reports mixed financial performance in 2025 with $49.17M in revenue, up 1.6% from 2024, but operating income dropped 80.59% to $0.68M due to factory relocation costs and increased R&D spending. Key R&D initiatives include RegenMatrix clinical trials, Cellular Matrix US market access (RL-04), and BBI Implants development. The company faces liquidity challenges, disclosing a $1.85M cash balance and negative operating cash flow, raising concerns about its ability to continue as a going concern. Significant partnerships include MiMedx and OPKO Health for product distribution.
2026-05-14 · 0001829126-26-005228
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Regenlab USA Inc. reports improved financial performance in 2024 with revenue increasing to $48.38M (+1.2% YoY), driven by international growth in Europe and select markets, while U.S. sales declined due to channel realignment. The company highlights expanded gross margins (71.4%) from high-margin PRP+HA products, cost optimization reducing G&A and marketing expenses by $1.2M, and increased R&D investment to $3.85M. Strategic partnerships like OPKO Health (Spain/Europe) and MiMedx are expected to restore U.S. growth. Key product lines include PRP kits (61% of revenue) and CellularMatrix (27%), with a focus on regenerative biologics and tissue engineering platforms.
2026-01-30 · 0001829126-26-000803
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Regenlab USA Inc. reported improved financial performance in 2024, with revenue increasing to $48.38M (+1.2% YoY), driven by growth in Europe and international markets, while U.S. sales declined due to channel realignment. The company achieved a net income of $1.01M in 2024 compared to a $2.95M loss in 2023, supported by cost optimization, gross margin expansion to 71.4%, and R&D investments. Strategic partnerships with MiMedx and OPKO Health, along with new product launches, are expected to drive future growth. The company also secured a $5M SBA-guaranteed loan and remains focused on expanding its regenerative biologics portfolio.
2025-10-20 · 0001829126-25-008214